Invuity, Inc. (NASDAQ:IVTY) announced its earnings results on Tuesday. The medical instruments supplier reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by $0.07, Bloomberg Earnings reports. Invuity had a negative net margin of 118.92% and a negative return on equity of 129.81%. The firm had revenue of $9.77 million for the quarter, compared to the consensus estimate of $10.30 million.

Invuity (NASDAQ IVTY) traded down 6.646% during trading on Wednesday, hitting $7.375. The company had a trading volume of 168,759 shares. The company’s market capitalization is $125.18 million. The firm has a 50-day moving average of $7.42 and a 200 day moving average of $7.61. Invuity has a 12-month low of $4.50 and a 12-month high of $14.25.

A number of equities analysts recently weighed in on the company. Piper Jaffray Companies reiterated a “buy” rating and issued a $10.00 price target on shares of Invuity in a research report on Wednesday. Northland Securities set a $13.00 price target on Invuity and gave the company a “buy” rating in a research report on Tuesday, June 13th. Zacks Investment Research lowered Invuity from a “hold” rating to a “sell” rating in a research report on Tuesday, June 13th. William Blair reiterated a “buy” rating on shares of Invuity in a research report on Tuesday, May 23rd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 price target (up previously from $9.00) on shares of Invuity in a research report on Thursday, April 27th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $15.17.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/26/invuity-inc-nasdaqivty-announces-quarterly-earnings-results-misses-estimates-by-0-07-eps.html.

In other Invuity news, Director Reza Zadno sold 4,000 shares of the business’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $9.16, for a total value of $36,640.00. Following the completion of the transaction, the director now directly owns 8,800 shares of the company’s stock, valued at $80,608. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Eric W. Roberts bought 6,500 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was acquired at an average cost of $7.07 per share, with a total value of $45,955.00. Following the completion of the purchase, the director now owns 106,029 shares of the company’s stock, valued at approximately $749,625.03. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 13,500 shares of company stock valued at $102,955. 10.50% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC boosted its position in Invuity by 0.5% in the first quarter. FMR LLC now owns 829,564 shares of the medical instruments supplier’s stock worth $6,595,000 after buying an additional 4,264 shares during the last quarter. Lyon Street Capital LLC boosted its position in Invuity by 84.3% in the first quarter. Lyon Street Capital LLC now owns 727,032 shares of the medical instruments supplier’s stock worth $5,780,000 after buying an additional 332,593 shares during the last quarter. Dialectic Capital Management LP boosted its position in Invuity by 67.7% in the first quarter. Dialectic Capital Management LP now owns 394,000 shares of the medical instruments supplier’s stock worth $3,132,000 after buying an additional 159,000 shares during the last quarter. Cowen Prime Services LLC boosted its position in Invuity by 10.7% in the first quarter. Cowen Prime Services LLC now owns 342,250 shares of the medical instruments supplier’s stock worth $2,721,000 after buying an additional 33,000 shares during the last quarter. Finally, Granite Investment Partners LLC boosted its position in Invuity by 90.4% in the first quarter. Granite Investment Partners LLC now owns 275,320 shares of the medical instruments supplier’s stock worth $2,189,000 after buying an additional 130,724 shares during the last quarter. 69.37% of the stock is owned by hedge funds and other institutional investors.

Earnings History for Invuity (NASDAQ:IVTY)

Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.